Info: Read More
  • 中药标准品生产商,产品定制服务
  • 常春藤苷C; 常春藤皂苷C

    Hederacoside C

    常春藤苷C; 常春藤皂苷C
    产品编号 CFN90183
    CAS编号 14216-03-6
    分子式 = 分子量 C59H96O26 = 1221.38
    产品纯度 >=98%
    物理属性 White powder
    化合物类型 Triterpenoids
    植物来源 The herbs of Hedera nepalensis.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    常春藤苷C; 常春藤皂苷C CFN90183 14216-03-6 10mg QQ客服:2056216494
    常春藤苷C; 常春藤皂苷C CFN90183 14216-03-6 20mg QQ客服:2056216494
    常春藤苷C; 常春藤皂苷C CFN90183 14216-03-6 50mg QQ客服:2056216494
    常春藤苷C; 常春藤皂苷C CFN90183 14216-03-6 100mg QQ客服:2056216494
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • National Hellenic Research Foundation (Greece)
  • Stanford University (USA)
  • S.N.D.T. Women's University (India)
  • University of Leipzig (Germany)
  • Washington State University (USA)
  • University of the Basque Country (Spain)
  • University of Liège (Belgium)
  • Periyar University (India)
  • Subang Jaya Medical Centre (Malaysia)
  • Sanford Burnham Medical Research Institute (USA)
  • Monash University Sunway Campus (Malaysia)
  • Universite de Lille1 (France)
  • The Australian National University (Australia)
  • Yale University (USA)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Int J Mol Sci.2022, 23(23):15213.
  • Planta Medica International2022, 9(01):e108-e115.
  • Chemistry of Plant Materials.2019, 129-136
  • Biomedicines.2021, 9(8):954.
  • Eur J Pharm Sci.2016, 94:33-45
  • Integr Med Res.2021, 10(3):100723.
  • Biofactors.2018, 44(2):168-179
  • International J of Green Pharmacy2019, 13(3)
  • Phytomedicine.2021, 84:153501.
  • Molecules.2020, 25(23):5556.
  • 2023, 24(6):5769.Int J Mol Sci.
  • Journal of Functional Foods2022, 99: 105331.
  • J Sep Sci.2018, 41(7):1682-1690
  • Int J Mol Sci.2019, 20(21):E5488
  • Institute of Food Science & Technology2021, 56(11).
  • Huazhong Agricultural University2022, pp34.
  • J Sci Food Agric.2018, 98(3):1153-1161
  • Front Pharmacol.2020, 11:566490.
  • Nutrients.2020, 12(11):3448.
  • Korean j.of Pharm.2017, 70-76
  • Food Chemistry2023, 137837.
  • Food Chemistry: X2023, 101032.
  • Environ Toxicol.2019, 34(4):513-520.
  • ...
  • 生物活性
    Description: Hederacoside C is one of the active ingredients in Hedera helix leaf extract (Ivy Ex.) and AG NPP709, a new botanical drug to treat acute respiratory infection and chronic inflammatory bronchitis. Hederacoside C has antispasmodic activity. Hederacoside C is a potent competitive inhibitor for serine protease porcine pancreatic elastase, shows comparable IC 50 value is 40.6 uM; it also non-competitively inhibits hyaluronidase activity in a dose- dependent fashion, shows comparable IC 50 value is 280.4 uM.
    In vitro:
    Phytomedicine. 2011 Jan 15;18(2-3):214-8.
    Pre-treatment with α-hederin increases β-adrenoceptor mediated relaxation of airway smooth muscle.[Pubmed: 20637581]
    Preparations of ivy leaves dry extract with secretolytic and bronchiolytic efficacy are widely used for the treatment of acute and chronic obstructive airway diseases. The mechanism by which ivy preparations improve lung functions is not fully understood.
    METHODS AND RESULTS:
    Here, we tested the influence of the three main saponins of ivy, α-hederin, hederacoside C and hederagenin, on the contraction and relaxation behaviour of isolated bovine tracheal smooth muscle strips by isometric tension measurements. None of the tested compounds altered histamine or methacholine-induced contraction of the smooth muscle strips. In contrast, the isoprenaline-induced relaxation of 100μM methacholine precontracted muscle strips was significantly enhanced when pre-treated with 1μM of α-hederin for 18h. The pre-treatment with hederacoside C or hederagenin had no effect on isoprenaline-induced relaxation.
    CONCLUSIONS:
    For the first time the bronchiolytic effect of α-hederin was demonstrated by isometric tension measurements using bovine tracheal smooth muscle strips. α-Hederin increases isoprenaline-induced relaxation indirectly, probably by inhibiting heterologous desensitization induced by high concentrations of muscarinic ligands like methacholine.
    J Ethnopharmacol. 2011 Apr 12;134(3):796-802.
    The effect of the whole extract of common ivy (Hedera helix) leaves and selected active substances on the motoric activity of rat isolated stomach strips.[Pubmed: 21291987]
    The long tradition of using the dry extract of Hedera helix (common ivy) leaves in traditional and contemporary alternative medicine caused that many biological and pharmacological studies have been aimed at evaluating the effects of ivy. Some of the results suggest that Hedera helix extract possesses bronchodilatatory and antispasmodic activity. On the other hand, the symptoms of ivy intoxication in human and animals, as well as adverse-reactions observed during the therapy with ivy-based pharmaceuticals, indicate rather stimulant effect of the plant on smooth muscle. Thus, the aim of this study was to evaluate the effect of two main active substances extracted from the plant (α-hederin and Hederacoside C) and the whole dry extract of Hedera helix on the gut motility.
    METHODS AND RESULTS:
    The experiments were carried out on isolated stomach corpus and fundus strips. The tissues were isolated from rats. The experiments were performed in isotonic conditions. The results are expressed as the percent of the reaction caused by a reference contractile substance, acetylcholine. The obtained results revealed that α-hederin applied in the concentration ranged from 25 to 320μM significantly changed the spontaneous motoric activity of rat stomach smooth muscle. The observed reaction had always the same character, a contraction, and its force was concentration dependent. The second tested saponin, Hederacoside C, did not alter the motility of rat isolated stomach corpus and fundus strips when administered in the concentration up to 100 μM, however, if applied in the concentration of 350 μM it induced a remarkable concentration of smooth muscle. Eventually, the whole extract of Hedera helix in a dose containing 60 μM of Hederacoside C produced a strong contraction which strength was comparable with the reaction generated by acetylcholine.
    CONCLUSIONS:
    According to the results, it is very likely that α-hederin, but not Hederacoside C contributes to the contractile response of isolated stomach corpus and fundus strips to the application of Hedera helix leaves' extract.
    Planta Med. 1997 Apr;63(2):125-9.
    In vitro antispasmodic compounds of the dry extract obtained from Hedera helix.[Pubmed: 9140224]
    Commercial dry extract of Hedera helix L. is used for the treatment of disorders of the respiratory tract; it is standardized towards papaverine (papaverine equivalent value, PE, activity of 1 g test substance equivalent to the activity of x mg papaverine) by in vitro antispasmodic activity on isolated guinea-pig ileum with acetylcholine as spasmogen.
    METHODS AND RESULTS:
    In order to determine the phytochemical basis for the antispasmodic activity, bioassay guided fractionation and subsequent isolation of phenolic compounds (flavonols, caffeoylquinic acids) and saponins (Hederacoside C, alpha-hederin, hederagenin) was carried out. Fractions and isolates obtained were investigated for antispasmodic activity and their contribution to the activity of the extract was calculated. Significant activity was found for both saponins and phenolic compounds, the PE values being approx. 55 and 49 for alpha-hederin and hederagenin, 54 and 143 for quercetin and kaempferol, and 22 for 3,5-dicaffeoylquinic acid, respectively. In view of their relative high concentration the saponins contribute most to the anti-spasmodic activity, followed by dicaffeoylquinic acids and the flavonol derivatives.
    CONCLUSIONS:
    The results indicate that the summed PE value of the compounds mentioned is an acceptable agreement with the PE value of the whole extract determined biologically.
    In vivo:
    Xenobiotica. 2013 Nov;43(11):985-92.
    Pharmacokinetics of hederacoside C, an active ingredient in AG NPP709, in rats.[Pubmed: 23607546 ]
    1. Hederacoside C (HDC) is one of the active ingredients in Hedera helix leaf extract (Ivy Ex.) and AG NPP709, a new botanical drug to treat acute respiratory infection and chronic inflammatory bronchitis. However, information regarding its pharmacokinetic properties remains limited.
    CONCLUSIONS:
    2. Here, we report the pharmacokinetics of HDC in rats after intravenous administration of HDC (3, 12.5, and 25 mg/kg) and after oral administration of HDC, Ivy Ex., and AG NPP709 (equivalent to 12.5, 25, and 50 mg/kg HDC). 3. Linear pharmacokinetics of HDC were identified upon its intravenous administration at doses of 3-25 mg/kg. Intravenous administration of HDC results in relatively slow clearance (1.46-2.08 mL/min/kg) and a small volume of distribution at steady state (138-222 mL/kg), while oral administration results in a low absolute oral bioavailability (F) of 0.118-0.250%. The extremely low F of HDC may be due to poor absorption of HDC from the gastrointestinal (GI) tract and/or its decomposition therein.
    CONCLUSIONS:
    4. The oral pharmacokinetics of HDC did not differ significantly among pure HDC, Ivy Ex., and AG NPP709.
    J Pharm Biomed Anal . 2016 Sep 10;129:90-95.
    An ultra-high-performance liquid chromatography-tandem mass spectrometric method for the determination of hederacoside C, a drug candidate for respiratory disorder, in rat plasma[Pubmed: 27411171]
    Abstract Hederacoside C is a principal bioactive pharmaceutical ingredient of Hedera helix leaf extracts. H. helix extracts have long been used in folk medicine for the treatment of respiratory disorders. Currently, hederacoside C is investigated as a promising candidate for the treatment of respiratory diseases. In this study, an accurate, sensitive, rapid, and reliable bioanalytical method was developed for the determination of hederacoside C in rat plasma using ultra high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). For sample preparation, plasma proteins were precipitated with 0.1% acetic acid in acetonitrile. Waters UPLC BEH C18 (2.1mm I.D.×100mm, 1.7μm) column was used for chromatographic separation. A gradient elution of mobile phases consisting of 0.02% acetic acid in distilled water (solvent A) and 0.02% acetic acid in acetonitrile (solvent B) was used at a flow rate of 0.3mL/min. The multiple reaction monitoring (MRM) mode was used for mass spectrometric detection; the MRM transitions were m/z 1219.7→m/z 469.2 for hederacoside C and m/z 1108.3→m/z 221.2 for ginsenoside Rb1 (internal standard) in the negative ionization mode. A calibration curve was constructed in the range of 10-1000ng/mL. The intra- and inter-day precision and accuracy were within 5%. The developed UPLC-MS/MS method was successfully applied in a pharmacokinetic study of hederacoside C in rats. Hederacoside C was quickly but inadequately absorbed from the gastrointestinal tract of rats resulting in extremely low bioavailability and relatively slow clearance. Keywords: Hedera helix; Hederacoside C; Pharmacokinetics; Plasma; UPLC–MS/MS.
    Xenobiotica . 2013 Nov;43(11):985-92.
    Pharmacokinetics of hederacoside C, an active ingredient in AG NPP709, in rats[Pubmed: 23607546]
    Abstract 1. Hederacoside C (HDC) is one of the active ingredients in Hedera helix leaf extract (Ivy Ex.) and AG NPP709, a new botanical drug to treat acute respiratory infection and chronic inflammatory bronchitis. However, information regarding its pharmacokinetic properties remains limited. 2. Here, we report the pharmacokinetics of HDC in rats after intravenous administration of HDC (3, 12.5, and 25 mg/kg) and after oral administration of HDC, Ivy Ex., and AG NPP709 (equivalent to 12.5, 25, and 50 mg/kg HDC). 3. Linear pharmacokinetics of HDC were identified upon its intravenous administration at doses of 3-25 mg/kg. Intravenous administration of HDC results in relatively slow clearance (1.46-2.08 mL/min/kg) and a small volume of distribution at steady state (138-222 mL/kg), while oral administration results in a low absolute oral bioavailability (F) of 0.118-0.250%. The extremely low F of HDC may be due to poor absorption of HDC from the gastrointestinal (GI) tract and/or its decomposition therein. 4. The oral pharmacokinetics of HDC did not differ significantly among pure HDC, Ivy Ex., and AG NPP709.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 0.8187 mL 4.0937 mL 8.1875 mL 16.3749 mL 20.4687 mL
    5 mM 0.1637 mL 0.8187 mL 1.6375 mL 3.275 mL 4.0937 mL
    10 mM 0.0819 mL 0.4094 mL 0.8187 mL 1.6375 mL 2.0469 mL
    50 mM 0.0164 mL 0.0819 mL 0.1637 mL 0.3275 mL 0.4094 mL
    100 mM 0.0082 mL 0.0409 mL 0.0819 mL 0.1637 mL 0.2047 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    青葙苷H; Celosin H CFN91669 1623405-28-6 C47H72O20 = 957.06 10mg QQ客服:2159513211
    青葙苷I; Celosin I CFN91061 1807732-38-2 C53H82O24 = 1103.2 10mg QQ客服:1413575084
    青葙苷J; Celosin J CFN91152 1623405-29-7 C58H90O28 = 1235.3 5mg QQ客服:2056216494
    瓜子金皂苷XXXV; Polygalasaponin XXXV CFN95176 184479-28-5 C63H98O31 = 1351.5 5mg QQ客服:1413575084
    远志皂苷B; Onjisaponin B CFN90600 35906-36-6 C75H112O35 = 1573.69 5mg QQ客服:2159513211
    瓜子金皂苷XXXI; Polygalasaponin XXXI CFN90728 79103-90-5 C75H112O36 = 1589.67 5mg QQ客服:215959384
    瓜子金皂苷XLIX; Polygalasaponin XLIX CFN95117 1033593-12-2 C64H102O33 = 1399.47 10mg QQ客服:2056216494
    冬青苷XLVIII; Ilexoside XLVIII CFN91698 129095-76-7 C42H66O15 = 811.0 5mg QQ客服:2159513211
    川续断皂苷VI; 木通皂苷D; Asperosaponin VI CFN99766 39524-08-8 C47H76O18 = 929.10 20mg QQ客服:2159513211
    辽东楤木皂苷VII; Araloside VII CFN80402 340982-22-1 C54H88O24 = 1121.26 5mg QQ客服:2056216494

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产